These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29222280)

  • 1. Toward personalized treatment in Waldenström macroglobulinemia.
    Castillo JJ; Treon SP
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):365-370. PubMed ID: 29222280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of Waldenström macroglobulinemia in 2020.
    Castillo JJ; Treon SP
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
    Zanwar S; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
    Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
    J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
    Castillo JJ; Hunter ZR; Yang G; Treon SP
    Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to Sequence Therapies in Waldenström Macroglobulinemia.
    Sarosiek S; Treon SP; Castillo JJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Waldenström macroglobulinemia.
    Treon SP; Hunter ZR; Castillo JJ; Merlini G
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and Emerging Treatments for Waldenström Macroglobulinemia.
    Grimont CN; Castillo Almeida NE; Gertz MA
    Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.
    Ghafoor B; Masthan SS; Hameed M; Akhtar HH; Khalid A; Ghafoor S; Allah HM; Arshad MM; Iqbal I; Iftikhar A; Husnain M; Anwer F
    Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future therapeutic options for patients with Waldenström macroglobulinemia.
    Castillo JJ; Hunter ZR; Yang G; Argyropoulos K; Palomba ML; Treon SP
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):206-215. PubMed ID: 27825467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 15. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
    Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
    Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax in Previously Treated Waldenström Macroglobulinemia.
    Castillo JJ; Allan JN; Siddiqi T; Advani RH; Meid K; Leventoff C; White TP; Flynn CA; Sarosiek S; Branagan AR; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Patterson CJ; Hunter ZR; Davids MS; Furman RR; Treon SP
    J Clin Oncol; 2022 Jan; 40(1):63-71. PubMed ID: 34793256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significances of MYD88
    Meng Q; Cao XX; Li J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
    Treon SP; Sarosiek S; Castillo JJ
    Blood; 2024 Apr; 143(17):1702-1712. PubMed ID: 38211337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
    Amaador K; Kersten MJ; Minnema MC; Vos JMI
    Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical application of genomics in Waldenström macroglobulinemia.
    Branagan AR; Lei M; Treon SP; Castillo JJ
    Leuk Lymphoma; 2021 Aug; 62(8):1805-1815. PubMed ID: 33569985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.